Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine
/in International Publications, Malignant LymphomaHyperthermia-enhanced tumor accumulation and antitumor efficacy of a doxorubicin-conjugate with a novel macromolecular carrier system in mice with non-small cell lung cancer
/in International Publications, NSCLCDendritic cell vaccines for leukemia patients
/in Acute Leukemia, Chronic Leukemia, International PublicationsDendritic cell-based immunotherapy of malignant melanoma: success and limitations
/in International Publications, Malignant MelanomaRe: Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase 1 clinical trial
/in International Publications, Prostate CancerPhase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus
/in International Publications, Newcastle Disease VirusCounterpoint: Hyperthermia with radiation therapy for chest wall recurrences
/in Breast Cancer, Hyperthermia, International PublicationsPoint: Hyperthermia with radiation for chest wall recurrences
/in Breast Cancer, Hyperthermia, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer